To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™This bill proposes an amendment to title XI of the Social Security Act to equalize the negotiation period for drug price negotiations between small-molecule drugs and biologic candidates under the Drug Price Negotiation Program. The goal is to standardize the timeframe allowed for negotiating prices, potentially impacting how these two categories of drugs are priced under federal programs.
The bill seeks to create parity in negotiation periods for small-molecule and biologic drugs within the Drug Price Negotiation Program but did not advance beyond referral to a subcommittee and has since expired.
- Amends title XI of the Social Security Act to address negotiation periods under the Drug Price Negotiation Program.
- Focuses on equalizing the negotiation timeframe between small-molecule drugs and biologic candidates.
- The bill was referred to the Subcommittee on Health but did not progress further and is now classified as failed or expired.
['Manufacturers of small-molecule drugs and biologic drugs, as negotiation periods would be standardized.', 'Federal agencies involved in drug price negotiations, such as the Centers for Medicare & Medicaid Services (CMS).', 'Potentially, patients and healthcare payers if negotiation processes become more streamlined or equitable.']
['The bill does not provide details on implementation mechanisms or oversight provisions for enforcing equal negotiation periods.', 'Potential administrative challenges in adjusting existing negotiation frameworks to accommodate equalized periods.', 'No information on cost implications or funding mechanisms related to the changes.']
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health. It addresses a specific aspect of the Drug Price Negotiation Program, which is part of broader federal efforts to manage prescription drug costs. The bill did not advance beyond subcommittee referral and is now considered failed or expired.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Standardizing negotiation periods could influence the timing and strategy of drug price negotiations, potentially affecting drug availability or pricing dynamics.', 'Equalizing negotiation periods may impact administrative workload for agencies managing the program.', 'Could lead to changes in how pharmaceutical companies plan their market entry or pricing strategies for small-molecule versus biologic drugs.']
The absence of a full bill text and official summary limits detailed analysis. Transparency would be improved by providing comprehensive legislative text and cost assessments. Oversight considerations include monitoring how equalized negotiation periods affect drug pricing outcomes and administrative processes.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.